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Anellovirus Dynamics Are Associated 
With Primary Graft Dysfunction in Lung 
Transplantation
Joshua A. Blatter, MD, MPH,1 Tsuyoshi Takahashi, MD,2 Brigitte Mittler,2 Ruben G. Nava, MD,2  
Varun Puri, MD,2 Daniel Kreisel, MD, PhD,2,3 and David Wang, PhD3,4
Survival in lung transplant has lagged behind other solid-organ transplants.1 While chronic lung allograft 
dysfunction is considered the primary contributor to limited 
lung allograft survival, there is substantial morbidity and 
mortality that is associated with shorter term outcomes in 
lung transplant.
Primary graft dysfunction (PGD) occurs within the first 72 
hours after transplant. It is the leading early cause of death 
after lung transplant.2 PGD is characterized by impaired 
oxygenation (as measured by ratio of arterial oxygen partial 
pressure to inhaled oxygen fraction, Pao2/FiO2) and chest 
radiograph abnormalities.3 PGD is graded on a scale of 0–3, 
and higher grades of PGD are associated with a diminishing 
Pao2/FiO2 ratio. Patients with severe PGD require more pro-
longed mechanical ventilation following transplant, and have 
7 times the risk of 30-day mortality, when compared with 
those without PGD.2 While epidemiologic studies have sug-
gested that pretransplant recipient diagnosis can impact PGD 
incidence,4 the immunologic milieu associated with PGD is 
less well understood. Certain proinflammatory cytokines (eg, 
CCL2, CXCL10, interleukin-2, interferon-gamma) are charac-
teristic in patients with PGD,5 and the presence of preformed 
autoantibodies in the recipient may contribute to increased 
PGD risk.6 Due to organ ischemia and relative immune sup-
pression, solid-organ recipients have been proposed to have a 
distinctive microbiome at the time of transplant.7
The family Anelloviridae is composed of near-ubiquitous 
small circular DNA viruses8 that have been noted to bloom 
in the serum and bronchoalveolar lavage fluid (BAL) of lung 
transplant recipients.9,10 We focused our study of the peri-
transplant virome on anellovirus due to its established asso-
ciation with states of immunosuppression and with transplant 
outcomes of interest. In a recent case-control study of grade 
3 PGD patients versus non-PGD patients, alphatorquevirus 
(a genus of anellovirus) in BAL was noted to rise less rapidly 
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Lung Transplantation
Background. Primary graft dysfunction (PGD) is the leading cause of early death in lung transplant. Anelloviruses are 
small circular DNA viruses that have been noted to be present at elevated levels in immunosuppressed patients. They have 
been associated with both short- and long-term outcomes in lung transplant, and we hypothesized that anellovirus dynam-
ics might be associated with the development of PGD.  Methods. We analyzed alphatorquevirus (ie, an anellovirus 
genus) levels in whole blood samples from 64 adult lung transplant recipients.  Results. Patients with a relatively rapid rise 
in alphatorquevirus levels in the week following transplant were less likely to develop higher-grade PGD over the first 3 days 
following transplant (P = 0.031).  Conclusions. This study is the first to establish an association between the develop-
ment of PGD and a component of the blood virome. While it is not known whether anelloviruses directly affect outcomes in 
lung transplant, they may serve as a biomarker of immune status in lung transplant recipients.
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after allograft implantation in PGD cases when compared 
with controls.11 In pediatric patients, alphatorquevirus levels 
at 2 weeks posttransplant have already been shown to pre-
dict acute cellular rejection (ACR),12 another key short-term 
adverse outcome in lung transplant recipients. In the current 
study, we sought to examine whether these dynamic patterns 
of alphatorquevirus associated with PGD and ACR in previ-




The participants in this study were recruited as part of the 
lung transplant virome cohort. From July 2017 to August 
2018, a total of 64 consecutive patients (19 to 75 y of age, 
average 58 y) were enrolled at the Washington University/
Barnes-Jewish Transplant Center in Saint Louis, Missouri. 
Induction immunosuppression was standardized, with 62 
patients receiving basiliximab and methylprednisolone, and 
2 patients with evidence of donor-specific antibodies receiv-
ing thymoglobulin and methylprednisolone. Maintenance 
immunosuppression, including tacrolimus, mycophenolate, 
and prednisone, was applied per protocol, as was antiviral 
prophylaxis. This study was approved by the Washington 
University in St. Louis Institutional Review Board (ID 
201706125).
Anellovirus PCR Analysis
Nucleic acid was extracted from whole blood samples 
using the COBAS AmpliPrep Total Nucleic Acid Isolation Kit 
(Roche Diagnostics), according to manufacturer’s instruc-
tions. Before extraction, 425 μL of whole blood was mixed 
with an equal volume of the COBAS Specimen Pre-Extraction 
Reagent. Samples were eluted in 75 μL of buffer.
Alphatorquevirus levels in extracted samples were quan-
tified using TaqMan quantitative real-time PCR, targeting 
a conserved segment of the viral untranslated region.12,13 
The 3 μL extracted sample, TaqMan Fast Advanced Master 
Mix (Thermo Fisher), 0.9 μM AMTS forward primer 
(5′ GTGCCGIAGGTGAGTTTA 3′), 0.9 μM AMTAS 
reverse primer (5′ AGCCCGGCCAGTCC 3′), and 250 nM 
AMTPTU probe (5′ TCAAGGGGCAATTCGGGCT 3′, 
6-FAM/ZEN/3′IBFQ) were combined in 25 μL total reac-
tion volume. Cycling conditions were 50°C for 2 minutes 
and 95°C for 20 seconds, followed by 40 cycles of 95°C for 
1 second, and 60°C for 20 seconds. Betatorquevirus levels 
in extracted samples were likewise quantified using TaqMan 
quantitative real-time PCR, targeting a short segment 
near the ORF 2.12,14 The 3-μL extracted sample, TaqMan 
Fast Advanced Master Mix, 0.5 µM forward primer (5′ 
AGTTTATGCCGCCAGACG 3′), 0.5 μM reverse primer 
(5′ CCCTAGACTTCGGTGGTTTC 3′), and 250 nM probe 
(5′ ACTCACCTHCGGCACCCGC 3′, 6-FAM/TAMRA). 
Cycling conditions were 95°C for 20 seconds, followed by 
40 cycles of 95°C for 1 second and 60°C for 20 seconds. 
The ViiA 7 Real-Time PCR System (Applied Biosystems) 
was used with default ViiA 7 Software v1.2 settings. A plas-
mid control for each assay was used to generate a standard 
curve (alphatorquevirus: slope −3.67, R2 0.99; betatorquevi-
rus: slope −3.83, R2 0.99), and the detection limit was 30 
and 3 copies for alphatorquevirus and betatorquevirus, 
respectively. Samples below the detection limit were assigned 
a value at the bottom of rank order.
Assignment of Clinical Metadata
The participants’ pretransplant listing diagnoses were 
assigned to Group A (obstructive disease), Group B (pulmonary 
vascular disease), Group C (cystic fibrosis), and Group D (restric-
tive disease) per current United Network of Organ Sharing 
policy.15 The diagnosis of PGD was based on consensus guide-
lines developed by The International Society for Heart & Lung 
Transplantation Working Group on Primary Graft Dysfunction.3 
High-grade PGD was assessed as Grade 2 or 3 disease at any 
time point within the first 72 hours following transplant. ACR 
was diagnosed using transbronchial biopsies obtained at 1, 2, 
and 3 months following transplant. The definition of ACR 
was likewise based on International Society for Heart & Lung 
Transplantation consensus guidelines,16 and presence of ACR 
within the first 3 months (ie, “ever ACR”) was defined as Grade 1 
disease or above. If patients had insufficient data (ie, <2 monthly 
transbronchial biopsy specimens obtained within the first 3 mo), 
no assignment of “ever ACR” was made.
Statistical Analyses
Alphatorquevirus and betatorquevirus levels before and 
after transplant were compared with Spearman correlation. 
Pairwise comparison of PGD incidence among the pretrans-
plant diagnoses was made with Fisher exact testing. Bivariate 
analyses of alphatorquevirus copy number and outcomes of 
interest were assessed with Mann-Whitney testing. The rate 
of rise of alphatorquevirus was assessed as a copy number 
ratio between later and earlier time points, and ratios were 
compared by Mann-Whitney testing. Statistical analysis was 
performed with GraphPad Prism version 8.
RESULTS
Study Participants
The characteristics of lung transplant virome study partici-
pants are summarized in Table 1. The most common diagno-
ses were Group A and Group D. High-grade PGD was more 
prevalent among patients with restrictive than obstructive 
disease (P < 0.003). Of the 64 patients included in the study, 




























Immediate pre- and post-transplant
alphatorquevirus
p<0.0001
FIGURE 1. Levels of recipient blood alphatorquevirus, 1 day 
before transplant (pretransplant) and 1–2 days following transplant 
(posttransplant).
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52 patients had blood samples needed for the assessment of 
anellovirus rise in the first week posttransplant. Of the 64 
patients included in the study, 51 had sufficient data for “ever 
ACR” assessment. Five of 64 patients died in the first year fol-
lowing their transplant.
Alphatorquevirus and Betatorquevirus Levels in the 
First Week Following Transplant
Figure 1 shows levels of recipient blood alphatorquevirus 1 
day before transplant and 1–2 days after transplant. There is a 
significant correlation (P < 0.0001) between alphatorquevirus 
levels at these timepoints. Betatorquevirus levels were likewise 
correlated (P < 0.0001, analysis not shown). In Figure 2, the 
rate of alphatorquevirus rise is expressed as a ratio of 1 week 
posttransplant, when compared with 1 day before transplant. 
Patients with “ever-high PGD” (Grade 2+) had a significantly 
slower rate of rise in alphatorquevirus when compared with 
patients without high-grade PGD (P = 0.031). We generated a 
logistic regression model to assess effect size and confounding, 
but when we applied this technique, there was no significant 
association between alphatorquevirus and PGD. The associa-
tion between ever-high PGD and betatorquevirus was not sig-
nificant (P = 0.64). There was also no association between 
alphatorquevirus or betatorquevirus rate of rise and the sub-
sequent development of ACR (alphatorquevirus, P = 0.12; 
betatorquevirus, P = 0.59).
Alphatorquevirus Levels in the Subsequent Month 
Following Transplant
Because our prior study had shown an association between 
2 weeks posttransplant blood alphatorquevirus levels and the 
subsequent development of ACR, we investigated that rela-
tionship in this cohort, but there was not a significant asso-
ciation (P = 0.55). Since there was a statistical association 
between immediate posttransplant alphatorquevirus rate of 
rise and PGD, we evaluated anellovirus expansion over the 
first 5 weeks following transplant, and evaluated dynamic 
trends. Patients with prior PGD had a nonsignificant rise in 
alphatorquevirus level between 1 and 3 weeks posttransplant 
(Figure 3). Patients with a more rapid rise in alphatorquevirus 
level between 1 and 5 weeks posttransplant also had a non-
significant increase in the incidence of “ever ACR” in the first 
3 months following transplant (Figure 4).
DISCUSSION
We determined that blood anellovirus levels are associ-
ated with PGD in lung transplant recipients. The finding that 
TABLE 1.
Characteristics of LTV cohort
Characteristic
Prevalence 




Female sex 35 (55%) 17 (48%)
Age at transplant 57.9 (14.0) n/a
Ever primary graft dysfunction (PGD) 27 (42%) n/a
Ever high-grade PGD (2 or above) 18 (28%) n/a
Ever ACR 25 (49%) 9 (36%)
Pretransplant diagnosis   
Obstructive disease (Group A) 29 (45%) 6 (21%)
Pulmonary vascular disease (Group B) 3 (5%) 2 (67%)
Cystic fibrosis (Group C) 6 (9%) 2 (33%)
Restrictive disease (Group D) 26 (41%) 16 (62%)




























Ratio of 1wk post-/pre-transplant alphatorquevirus,
by ever-highPGD (2+) status
p=0.031
FIGURE 2. Levels of recipient blood alphatorquevirus, expressed as 
a ratio of 1 week posttransplant, when compared with 1 day before 
transplant, among patients without and with high-grade PGD (Grade 
























Ratio of 3 vs. 1wk post-transplant alphatorquevirus,
by everPGD status
p=0.074
FIGURE 3. Levels of recipient blood alphatorquevirus, expressed as 
a ratio of 3 week posttransplant, when compared with 1 week after 
transplant, among patients without and with PGD. PGD, primary graft 
dysfunction.
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a relatively rapid rise in peritransplant alphatorquevirus is 
associated with protection from PGD is analogous to existing 
literature that has found a comparably rapid rise in BAL.11 
The relatively low rate of PGD in patients with obstructive 
disease has likewise been noted previously.17 Nevertheless, this 
study is the first to identify a viral marker in the blood that 
is associated with the development of PGD in lung transplant 
recipients. These results need to be interpreted with caution 
due to small sample size, and because there is not a significant 
association between PGD and blood anellovirus when a mul-
tivariable analysis is applied.
We did not replicate the finding in our pediatric cohort, 
in whom a blood alphatorquevirus level drawn at 2 weeks 
following transplant could be used to predict subsequent epi-
sodes of ACR over the first 3 months following transplant.12 
While age-specific alterations in the virome are well-described 
in the human gut,18 there are little data about age-dependency 
of the virome in the human lung. Nevertheless, anellovirus 
prevalence has been established to change with the age of the 
human host,8 suggesting that there may be age-dependent 
changes in the human immune milieu that impact a host’s 
anellovirus population. It is also possible that we did not 
see this alphatorquevirus association with ACR in this adult 
cohort due to the small sample size.
While there were not significant associations between early 
anellovirus levels and the subsequent development of ACR in 
this adult cohort, we evaluated trends in anellovirus temporal 
dynamics. The now established lag in anellovirus expansion 
after transplant,19 rather than reflecting an uninterpretable 
flux until a steady state population is established, may itself 
hold clues as to the immune receptivity of a transplant recipi-
ent. An immediate rapid rise in anellovirus after transplant is 
associated with protection from PGD, while there is a nonsig-
nificant tendency toward subsequent slowing in anellovirus 
expansion in ACR-free patients. The significant association 
between rapid anellovirus rise and the protection from PGD 
did not hold up in a multivariable analysis; however, so fur-
ther study of anellovirus dynamics in the immediate post-
transplant period may be needed.
What is not clear from the present study is whether anello-
viruses have a direct effect on peritransplant host immunity, or 
whether they are reflective of a protectively immunosuppressed 
dysbiosis. Alphatorqueviruses encode miRNAs that inhibit inter-
feron response,20 and some anelloviruses can inhibit IL-6 and 
IL-8 transcription by interfering with NF-kappaB signaling.21 
Due to the lack of understanding regarding the anellovirus life 
cycle, it is not yet clear why anellovirus dynamics have associa-
tions with key clinical outcomes. Nevertheless, given the impor-
tance of toll-like receptor signaling in PGD,22 it is possible that 
that anellovirus levels reflect the state of host innate immunity.
There are potentially confounding factors at the time of trans-
plant, such as blood transfusion, that add to the complexity of 
delineating the role of anellovirus. We were unable to assess 
effect size and confounding in the current study since multivari-
able modeling showed no association between anellovirus and 
PGD. Given that the association present by bivariate analysis 
was not present in a multivariable analysis, it is possible that a 
larger cohort will be needed to evaluate posttransplant anello-
virus dynamics, or that there are, in fact, confounding variables 
limiting the applicability of these findings. The conclusions that 
can be drawn from this study are limited by sample size, and it 
is possible that a larger cohort would be needed to identify sig-
nificant trends in anellovirus expansion following transplant. 
Nevertheless, anellovirus has now been associated with several 
key outcomes in lung transplant, including PGD,11 ACR,12 and 
chronic lung allograft dysfunction,23 suggesting that it is a vital 
biomarker even if it does not impact human health. The devel-
opment of an animal model for anellovirus infection24 could 
help us to interpret host-pathogen dynamics.
ACKNOWLEDGMENTS
We thank the patients who have contributed to this study.
REFERENCES
 1. Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ 
transplant in the United States. JAMA Surg. 2015;150:252–259.
 2. Christie JD, Sager JS, Kimmel SE, et al. Impact of primary graft failure on 
outcomes following lung transplantation. Chest. 2005;127:161–165.
 3. Christie JD, Carby M, Bag R, et al; ISHLT Working Group on Primary 
Lung Graft Dysfunction. Report of the ISHLT Working Group on 
Primary Lung Graft Dysfunction part II: definition. A consensus state-
ment of the International Society for Heart and Lung Transplantation. 
J Heart Lung Transplant. 2005;24:1454–1459.
 4. Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk fac-
tors for primary graft failure following lung transplantation. Chest. 
2003;124:1232–1241.
 5. Bharat A, Kuo E, Steward N, et al. Immunological link between pri-
mary graft dysfunction and chronic lung allograft rejection. Ann Thorac 
Surg. 2008;86:189–95; discussion 196.
 6. Tiriveedhi V, Gautam B, Sarma NJ, et al. Pre-transplant antibodies 
to kα1 tubulin and collagen-V in lung transplantation: clinical correla-
tions. J Heart Lung Transplant. 2013;32:807–814.
 7. Xiao J, Peng Z, Liao Y, et al. Organ transplantation and gut micro-
biota: current reviews and future challenges. Am J Transl Res. 
2018;10:3330–3344.
 8. Ninomiya M, Takahashi M, Nishizawa T, et al. Development of PCR 
assays with nested primers specific for differential detection of three 
human anelloviruses and early acquisition of dual or triple infection 
during infancy. J Clin Microbiol. 2008;46:507–514.
 9. Young JC, Chehoud C, Bittinger K, et al. Viral metagenomics reveal 
blooms of anelloviruses in the respiratory tract of lung transplant recip-
ients. Am J Transplant. 2015;15:200–209.
 10. De Vlaminck I, Khush KK, Strehl C, et al. Temporal response of the 
human virome to immunosuppression and antiviral therapy. Cell. 
2013;155:1178–1187.
 11. Abbas AA, Diamond JM, Chehoud C, et al. The perioperative lung 
transplant virome: torque teno viruses are elevated in donor lungs 































FIGURE 4. Levels of recipient blood alphatorquevirus, expressed as 
a ratio of 5 week posttransplant, when compared with 1 week after 
transplant, among patients without and with PGD. ACR, acute cellular 
rejection; PGD, primary graft dysfunction.
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.  5Blatter et al
 12. Blatter JA, Sweet SC, Conrad C, et al. Anellovirus loads are associated 
with outcomes in pediatric lung transplantation. Pediatr Transplant. 
2018;22.
 13. Maggi F, Pifferi M, Fornai C, et al. TT virus in the nasal secretions of 
children with acute respiratory diseases: relations to viremia and dis-
ease severity. J Virol. 2003;77:2418–2425.
 14. García-Álvarez M, Berenguer J, Alvarez E, et al. Association of torque 
teno virus (TTV) and torque teno mini virus (TTMV) with liver disease 
among patients coinfected with human immunodeficiency virus and 
hepatitis C virus. Eur J Clin Microbiol Infect Dis. 2013;32:289–297.
 15. Wille KM, Harrington KF, deAndrade JA, et al. Disparities in lung trans-
plantation before and after introduction of the lung allocation score. J 
Heart Lung Transplant. 2013;32:684–692.
 16. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working 
formulation for the standardization of nomenclature in the diagnosis of 
lung rejection. J Heart Lung Transplant. 2007;26:1229–1242.
 17. Barr ML, Kawut SM, Whelan TP, et al; ISHLT Working Group on 
Primary Lung Graft Dysfunction. Report of the ISHLT Working Group 
on Primary Lung Graft Dysfunction part IV: recipient-related risk fac-
tors and markers. J Heart Lung Transplant. 2005;24:1468–1482.
 18. Lim ES, Zhou Y, Zhao G, et al. Early life dynamics of the human 
gut virome and bacterial microbiome in infants. Nat Med. 
2015;21:1228–1234.
 19. Görzer I, Jaksch P, Kundi M, et al. Pre-transplant plasma torque teno 
virus load and increase dynamics after lung transplantation. Plos One. 
2015;10:e0122975.
 20. Kincaid RP, Burke JM, Cox JC, et al. A human torque teno virus 
encodes a microrna that inhibits interferon signaling. Plos Pathog. 
2013;9:e1003818.
 21. Zheng H, Ye L, Fang X, et al. Torque teno virus (SANBAN isolate) 
ORF2 protein suppresses NF-kappab pathways via interaction with 
ikappab kinases. J Virol. 2007;81:11917–11924.
 22. Diamond JM, Wigfield CH. Role of innate immunity in primary graft 
dysfunction after lung transplantation. Curr Opin Organ Transplant. 
2013;18:518–523.
 23. Görzer I, Jaksch P, Strassl R, et al. Association between plasma 
torque teno virus level and chronic lung allograft dysfunction after lung 
transplantation. J Heart Lung Transplant. 2017;36:366–368.
 24. Nishiyama S, Dutia BM, Stewart JP, et al. Identification of novel anelloviruses 
with broad diversity in UK rodents. J Gen Virol. 2014;95(Pt 7):1544–1553.
